Long-term follow-up of people with hepatitis B treated with imdusiran
Follows adults with chronic hepatitis B who previously received imdusiran and remain off therapy.
Plain-language title generated from the registry record
Registry title: Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
Key facts
- Where
- Changhua, Chiayi City, Kaohsiung City, Taichung, and Taoyuan, TaiwanSee the 6 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with chronic hepatitis B who took imdusiran in an earlier trial, stopped NA therapy there, and are still off it.
- Age
- 20 Years to 70 Years
- Sex
- All sexes
- Disease stage
- Chronic hepatitis B; less than 3 years of follow-up visits completed after stopping NA therapy in the earlier trial.
- Earlier treatment
- Must have taken part in an earlier imdusiran trial, stopped NA therapy in that trial, and still be off NA therapy.
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 70 years old?
Source: NCT06277037, who can take part
Where in Taiwan
- Changhua Christian HospitalChanghua, TaiwanContact: Pei-Yuan SuTaking people
- Chia-Yi Christian HospitalChiayi City, TaiwanContact: Chi-Yi ChenTaking people
- E-DA HospitalKaohsiung City, TaiwanContact: Gin-Ho LoTaking people
- Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung City, TaiwanContact: Wan-Long ChuangTaking people
- Taichung Veterans General HospitalTaichung, TaiwanContact: Sheng-Shun YangTaking people
- Chang Gung Medical Foundation - LinkouTaoyuan, TaiwanContact: Chao-Wei HsuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Arbutus Biopharma Corporation
- Trial code
- NCT06277037
- Record updated
- 27 November 2024
- Original description
This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study [EOS] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).Read full original descriptionShow less
A Long-Term Follow-up Study for Subjects With Chronic Hepatitis B Previously Treated With Imdusiran (AB-729)
This is a long term follow-up study for chronic hepatitis B (CHB) subjects who have received imdusiran treatment in a prior clinical trial, stopped NA therapy during that trial, and remain off therapy. Subjects may enroll after completing the end of study visit (baseline visit within 12 weeks ± 1 week from the end of study [EOS] visit) from their imdusiran clinical trial (the "parent study"). No interventions will be performed in this study other than blood sample collections, review of current medications, and reporting of any adverse events related to study procedures or NA therapy if restarted. Study participation will be for approximately 2 years (to complete a total of at least 3 years of follow-up while off NA therapy, inclusive of parent study participation).
Inclusion: Have participated in a prior imdusiran clinical trial,; Have discontinued NA therapy in that trial and remain off NA therapy,; Have completed less than 3 years of follow-up visits after NA discontinuation in the parent study; Have the ability to review and provide signed informed consent which includes compliance with all protocol-specified visit schedules and requirements.
Exclusion: Not applicable.